Abstract
Lecanemab (lecanemab-irmb; LEQEMBI™) is a humanized immunoglobulin gamma 1 (IgG1) against aggregated soluble and insoluble forms of amyloid-β peptide. It is being developed by Eisai, under a global licence from BioArctic (formerly BioArctic Neuroscience), and in collaboration with Biogen, for the treatment of Alzheimer's disease, and received its first approval for this indication on 6 January 2023 in the USA under the Accelerated Approval Pathway. According to the US prescribing information, treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, and a confirmed presence of amyloid beta pathology (i.e. the population in which treatment was initiated in clinical trials). There are no effectiveness or safety data on initiating treatment at earlier or later stages of the disease than were studied. Lecanemab is undergoing regulatory review in the EU, Japan and China, with clinical development underway in several other countries worldwide. This article summarizes the milestones in the development of lecanemab leading to this first approval for the treatment of Alzheimer’s disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer’s disease. Lancet. 2021;397(10284):1577–90.
Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Primers. 2021;7(1):33.
US FDA. FDA grants accelerated approval for Alzheimer’s disease treatment [media release]; 6 Jan 2023. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment.
Dhillon S. Aducanumab: first approval. Drugs. 2021;81(12):1437–43.
Eisai Inc. LEQEMBI™ (lecanemab-irmb) injection, for intravenous use: US prescribing information; 2023. https://www.fda.gov/. Accessed 10 Jan 2023.
Eisai Co. Ltd. FDA approves LEQEMBI™ (lecanemab-irmb) under the accelerated approval pathway for the treatment of Alzheimer's disease [media release]; 6 Jan 2023. http://www.eisai.com.
Eisai. Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease [media release]; 6 Jan 2023. https://www.eisai.com/.
Eisai Co. Ltd. Eisai submits Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease in Europe [media release]; 11 Jan 2023. https://www.eisai.com/.
Eisai Co. Ltd. Eisai files Marketing Authorization Application for anti-amyloid-beta protofibril antibody lecanemab for early Alzheimer's disease in Japan [media release]; 16 Jan 2023. https://www.eisai.com/.
Eisai Co Ltd. Eisai initiates BLA submission of data for lecanemab in China [media release]; 22 Dec 2022. http://www.eisai.com.
BioArctic. Project portfolio; 2023. https://www.bioarctic.se/en/project-portfolio-1921/. Accessed 25 Jan 2023.
The Dominantly Inherited Alzheimer Network. Update on the DIAN-TU-001 trial with E2814 and lecanemab (Eisai Co., Ltd) [media release]; 7 Jan 2023. https://dian.wustl.edu/update-on-the-dian-tu-001-trial-with-e2814-and-lecanemab-eisai-co-ltd/.
Eisai Co. Ltd., BioArctic Neuroscience Inc. Eisai announces strategic alliance with BioArctic Neuroscience to develop immunotherapy for Alzheimer's disease [media release]; 26 Aug 2005. http://www.eisai.co.jp.
Eisai Co. Ltd., BioArctic Neuroscience A. B. Eisai and BioArctic Neuroscience enter exclusive licensing agreement with novel antibody treatment for Alzheimer's disease [media release]; 4 Dec 2007. http://www.eisai.co.jp.
BioArctic Neuroscience A. B. Innovative Alzheimer therapy: a new license agreement between BioArctic and Eisai on back-up program to BAN2401 [media release]; 28 Sep 2015. http://www.bioarctic.se.
BioArctic. BioArctic announces research collaboration with Eisai regarding BAN2401 [media release]; 17 Dec 2019. http://www.bioarctic.com.
Eisai Co. Ltd., Biogen Idec. Eisai and Biogen Idec enter collaboration to develop and commercialize Alzheimer's disease treatments [media release]; 5 Mar 2014. http://www.eisai.com.
Söderberg L, Johannesson M, Nygren P, et al. Lecanemab, aducanumab, and gantenerumab: binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease. Neurotherapeutics. 2022. https://doi.org/10.1007/s13311-022-01308-6.
Tucker S, Möller C, Tegerstedt K, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575–88.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.
BioArctic. BioArctic's partner Eisai presents results of lecanemab phase 3 confirmatory Clarity AD study for early Alzheimer's disease at CTAD conference [media release]. 30 Nov 2022.
Eisai Co. Ltd. Latest findings on lecanemab: clinical efficacy, ARIA rates, biomarkers relationship to clinical outcomes and dosing regimens. Presented at AD/PDTM 2022 Annual Meeting [media release]. 22 Mar 2022. http://www.eisai.com.
McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191.
Hayato S, Takenaka O, Sreerama Reddy SH, et al. Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease. CPT Pharmacometrics Syst Pharmacol. 2022;11(12):1578-91.
Sabbagh M, van Dyck CH. Response to: multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med. 2023;388(5):480.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Hoy, S.M. Lecanemab: First Approval. Drugs 83, 359–365 (2023). https://doi.org/10.1007/s40265-023-01851-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-023-01851-2